Negative regulators of angiogenesis in inflammatory bowel disease: Thrombospondin in the spotlight

Research output: Contribution to journalArticle

Abstract

Angiogenesis is the growth of new blood vessels. In the two major forms of inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis, robust angiogenesis exists, and its blockade may have therapeutic potential, as shown in animal models of experimental intestinal inflammation. While abundant literature is available on the positive regulators of intestinal pathological angiogenesis, e.g. VEGF, b-FGF, IL-8, CD40 and CD40L, almost no data exist on negative regulators. Thrombospondin-1 is a negative regulator of angiogenesis, and it plays a new role in IBD-associated angiogenesis. In addition, recombinant thrombospondin-1 may inhibit pathological angiogenesis and may offer a new therapeutic approach to intestinal inflammation.

Original languageEnglish
Pages (from-to)22-24
Number of pages3
JournalPathobiology
Volume75
Issue number1
DOIs
Publication statusPublished - Mar 2008

Keywords

  • Crohn's disease
  • Endothelium
  • Inflammatory bowel disease
  • Ulcerative colitis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Clinical Biochemistry
  • Immunology and Allergy
  • Cell Biology

Fingerprint Dive into the research topics of 'Negative regulators of angiogenesis in inflammatory bowel disease: Thrombospondin in the spotlight'. Together they form a unique fingerprint.

  • Cite this